Eisai Co., Ltd. and Consolidated Subsidiaries Third Quarter Financial Report |
 |
[ Forward-looking Statements and Risk Factors ]
Materials and information provided in this financial disclosure may contain “forward-looking statements” based on current expectations, forecasts, estimates, business goals and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions, such as interest rate and currency exchange fluctuations.
Risks that may cause significant fluctuations in the consolidated results of the Company or have a material effect on decisions of shareholders are described below. These are risk factors that have been identified and assessed as of the disclosure date of the Financial Report. Risk factors associated with our business include, but are not limited to, challenges arising out of global expansion, uncertainties in new drug development, risks related to strategic alliances with partners, healthcare cost-containment measures, intensified competition with generic drugs, intellectual property, possible incidence of adverse events, compliance with laws and regulations, litigation, closure or shutdown of factories, safety issues of raw materials used, outsourcing-related risks, environmental issues, IT security/information management, and conditions of financial markets, foreign exchange fluctuations, and internal control systems.
|
|
Notes for all amounts and exchange rate
• Revisions have been made to the full-year consolidated forecast announced previously. The revised parts are underlined.
• All amounts are rounded to their nearest specified unit.
• The exchange rates used in the reference data are noted in the table below.
• All amounts of overseas profit and loss are converted into yen based on the average exchange rates for the periods shown in the table below.
 Jump to Currency Exchange Rates
|
[Consolidated]
[Non-Consolidated]
- Non-Consolidated Financial Highlights
<About Indications in this Reference Data>
Eisai believes that cash generating ability is the most intrinsic element determining the true value of a company. Upon this basic concept, in order to reflect our true earnings capacity, we focus on disclosing “cash income” and “cash EPS,” which are not affected by non-cash profit-and-loss items, such as depreciation of property, plant and equipment, amortization of goodwill, loss on impairment (including loss on devaluation of investment securities), and in-process R&D expenses.
Cash income
Cash income is the total amount of cash available for investment in future growth and business development, dividend payments, repayment of borrowings, and other expenditures. We consider cash income as an indicator to assess corporate growth potential and strategies.
Cash income =Net income + Depreciation of PP&E and amortization of intangible assets + In-process R&D expenses + Amortization of goodwill + loss on impairment of long-lived assets (including loss on devaluation of investment securities)
Cash income per share (Cash EPS)
Cash EPS = Cash income / Number of shares issued and outstanding at the end of the year after deducting treasury stocks
 | The files are in Adobe Acrobat Format. To view them you will need to download the Adobe Reader.Adobe Reader, the Acrobat logo are trademarks of Adobe Systems Incorporated. |
|
/USD)
